Show simple item record

dc.contributor.authorDancy, J.G.
dc.contributor.authorWadajkar, A.S.
dc.contributor.authorConnolly, N.P.
dc.contributor.authorGalisteo, R.
dc.contributor.authorAmes, H.M.
dc.contributor.authorGoloubeva, O.G.
dc.contributor.authorWoodworth, G.F.
dc.contributor.authorWinkles, J.A.
dc.contributor.authorKim, A.J.
dc.date.accessioned2020-02-04T16:19:38Z
dc.date.available2020-02-04T16:19:38Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85078176625&doi=10.1126%2fsciadv.aax3931&partnerID=40&md5=6bebae3ebb86100ca3993a7f905f508a
dc.identifier.urihttp://hdl.handle.net/10713/11659
dc.description.abstractDevelopment of effective tumor cell–targeted nanodrug formulations has been quite challenging, as many nanocarriers and targeting moieties exhibit nonspecific binding to cellular, extracellular, and intravascular components. We have developed a therapeutic nanoparticle formulation approach that balances cell surface receptor-specific binding affinity while maintaining minimal interactions with blood and tumor tissue components (termed “DART” nanoparticles), thereby improving blood circulation time, biodistribution, and tumor cell–specific uptake. Here, we report that paclitaxel (PTX)–DART nanoparticles directed to the cell surface receptor fibroblast growth factor–inducible 14 (Fn14) outperformed both the corresponding PTX-loaded, nontargeted nanoparticles and Abraxane, an FDA-approved PTX nanoformulation, in both a primary triple-negative breast cancer (TNBC) model and an intracranial model reflecting TNBC growth following metastatic dissemination to the brain. These results provide new insights into methods for effective development of therapeutic nanoparticles as well as support the continued development of the DART platform for primary and metastatic tumors. Copyright 2020 The Authorsen_US
dc.description.sponsorshipThis research was supported in part by the National Institutes of Health [R37 CA218617 (A.J.K.) and R01 NS107813 (G.F.W.)] and an Institutional Research Grant IRG-97-153-10 (A.S.W.) from the American Cancer Society. J.G.D., A.S.W., and N.P.C. were supported in part by NIH Training Grant T32 CA154274. J.G.D. was also supported by an NIGMS Initiative for Maximizing Student Development Grant (R25 GM55036).en_US
dc.description.urihttps://doi.org/10.1126/sciadv.aax3931en_US
dc.language.isoen_USen_US
dc.publisherAmerican Association for the Advancement of Scienceen_US
dc.relation.ispartofScience Advances
dc.subjecttherapeutic nanoparticlesen_US
dc.subject.lcshBreast--Canceren_US
dc.subject.meshNanoparticlesen_US
dc.titleDecreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast canceren_US
dc.typeArticleen_US
dc.identifier.doi10.1126/sciadv.aax3931


This item appears in the following Collection(s)

Show simple item record